Abstract
Mammalian expression systems such as Chinese hamster ovary (CHO), mouse myeloma (NS0), and human embryonic kidney (HEK) cells serve a critical role in the biotechnology industry as the production host of choice for recombinant protein therapeutics. Most of the recombinant biologics are glycoproteins that contain complex oligosaccharide or glycan attachments representing a principal component of product quality. Both N-glycans and O-glycans are present in these mammalian cells, but the engineering of N-linked glycosylation is of critical interest in industry and many efforts have been directed to improve this pathway. This is because altering the N-glycan composition can change the product quality of recombinant biotherapeutics in mammalian hosts. In addition, sialylation and fucosylation represent components of the glycosylation pathway that affect circulatory half-life and antibody-dependent cellular cytotoxicity, respectively. In this chapter, we first offer an overview of the glycosylation, sialylation, and fucosylation networks in mammalian cells, specifically CHO cells, which are extensively used in antibody production. Next, genetic engineering technologies used in CHO cells to modulate glycosylation pathways are described. We provide examples of their use in CHO cell engineering approaches to highlight these technologies further. Specifically, we describe efforts to overexpress glycosyltransferases and sialyltransfereases, and efforts to decrease sialidase cleavage and fucosylation. Finally, this chapter covers new strategies and future directions of CHO cell glycoengineering, such as the application of glycoproteomics, glycomics, and the integration of ‘omics’ approaches to identify, quantify, and characterize the glycosylated proteins in CHO cells.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- ADCC:
-
Antibody-dependent cellular cytotoxicity
- Asn:
-
Asparagine
- BHK:
-
Baby hamster kidney
- CDC:
-
Complement-dependent cytotoxicity
- CHO:
-
Chinese hamster ovary
- CMP-SAT:
-
cytidine 5′-monophosphate (CMP)-sialic acid transporter
- CRISPR:
-
Clustered regularly interspaced short palindromic repeats
- Dol-P:
-
Dolichol phosphate
- EPO:
-
Erythropoietin
- ER:
-
Endoplasmic reticulum
- ESI-MS:
-
Electrospray ionization mass spectrometry
- Fc:
-
Fragment crystallizable
- FcγRIIIa:
-
Fc gamma receptor IIIa
- FUT8:
-
α-1,6-fucosyltransferase
- FX:
-
GDP-4-keto-6-d-deoxymannose epimerase/GDP-4-keto-6-l-galactose reductase
- GFPP:
-
GDP-fucose pyrophosphorylase
- GFT:
-
GDP-fucose transporter
- GlcNAc:
-
N-acetylglucosamine
- GMD:
-
GDP-fucose 4,6-dehydratase
- GNE/MNK:
-
Uridine diphosphate-N-acetyl glucosamine 2-epimerase/N-acetyl mannosamine kinase
- GnT-1 or Mgat1:
-
N-acetylglucosaminyltransferase I
- GnT-II or Mgat2:
-
Beta-1,2-N-acetylglucosaminyltransferase II
- GnT-III or Mgat3:
-
Beta-1,4-N-acetylglucosaminyltransferase III
- GnT-IV or Mgat 4:
-
Beta-1,2-N-acetylglucosaminyltransferase IV
- GnT-V or Mgat 5:
-
Beta-1,2-N-acetylglucosaminyltransferase V
- HEK:
-
Human embryonic kidney
- HNF1-alpha:
-
Hepatocyte nuclear factor 1-alpha
- HPLC:
-
High-performance liquid chromatography
- LacNAc:
-
Acetyl lactosamine
- mAb:
-
Monoclonal antibody
- MALDI-TOF:
-
Matrix-assisted laser desorption/ionization time-of-flight
- ManII:
-
Alpha-mannosidase II
- Neu5Gc:
-
N-glycolylneuraminic acid
- NK:
-
Natural killer
- OST:
-
Oligosaccharyltransferase
- RCA-I:
-
Ricinus communis agglutinin I
- Ser:
-
Serine
- shRNA:
-
Short hairpin RNA
- siRNA:
-
Small interfering RNA
- SPEG:
-
Solid phase extraction of glycosylated peptides
- TALEN:
-
Transcription activator-like effector nuclease
- Thr:
-
Threonine
- tPA:
-
Tissue plasminogen activator
- ZFN:
-
Zinc finger nuclease
References
Ghaderi D et al (2012) Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol Genet Eng Rev 28:147–175
Hossler P, Khattak SF, Li ZJ (2009) Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 19(9):936–949
Lepenies B, Seeberger PH (2014) Simply better glycoproteins. Nat Biotechnol 32(5):443–445
Aggarwal RS (2014) What’s fueling the biotech engine-2012 to 2013. Nat Biotechnol 32(1):32–39
Jiménez D et al (2005) Contribution of N-linked glycans to the conformation and function of intercellular adhesion molecules (ICAMs). J Biol Chem 280(7):5854–5861
Agrawal P et al (2014) Mapping posttranscriptional regulation of the human glycome uncovers microRNA defining the glycocode. Proc Natl Acad Sci 111(11):4338–4343
Palomares LA, Estrada-Mondaca S, Ramirez OT (2004) Production of recombinant proteins: challenges and solutions. Methods Mol Biol 267:15–52
Walsh G, Jefferis R (2006) Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 24(10):1241–1252
Gavel Y, Vonheijne G (1990) Sequence differences between glycosylated and nonglycosylated Asn-X-Thr Ser acceptor sites – implications for protein engineering. Protein Eng 3(5):433–442
Stavenhagen K et al (2013) Quantitative mapping of glycoprotein micro-heterogeneity and macro-heterogeneity: an evaluation of mass spectrometry signal strengths using synthetic peptides and glycopeptides. J Mass Spectrom 48(6):i
Wang Q et al (2017) Glycoengineering of CHO cells to improve product quality. Methods Mol Biol 1603:25–44
Varki A, Schauer R (2009) Sialic acids. In: Varki A et al (eds) Essentials of glycobiology. Cold Spring Harbor, New York
Aebi M (2013) N-linked protein glycosylation in the ER. Biochim Biophys Acta 1833(11):2430–2437
Aebi M et al (2010) N-glycan structures: recognition and processing in the ER. Trends Biochem Sci 35(2):74–82
Butler M, Meneses-Acosta A (2012) Recent advances in technology supporting biopharmaceutical production from mammalian cells. Appl Microbiol Biotechnol 96(4):885–894
Swiech K, Picanco-Castro V, Covas DT (2012) Human cells: new platform for recombinant therapeutic protein production. Protein Expr Purif 84(1):147–153
Padler-Karavani V, Varki A (2011) Potential impact of the non-human sialic acid N-glycolylneuraminic acid on transplant rejection risk. Xenotransplantation 18(1):1–5
Bosques CJ et al (2015) Chinese hamster ovary cells can produce galactose-alpha-1, 3-galactose antigens on proteins (vol 28, pg 1153, 2010). Nat Biotechnol 16(10):23849–23866
Muchmore EA et al (1989) Biosynthesis of N-glycolyneuraminic acid. The primary site of hydroxylation of N-acetylneuraminic acid is the cytosolic sugar nucleotide pool. J Biol Chem 264(34):20216–20223
Chung CH et al (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358(11):1109–1117
Butler M, Spearman M (2014) The choice of mammalian cell host and possibilities for glycosylation engineering. Curr Opin Biotechnol 30:107–112
Croset A et al (2012) Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells. J Biotechnol 161(3):336–348
Zhao Y et al (2008) Branched N-glycans regulate the biological functions of integrins and cadherins. FEBS J 275(9):1939–1948
Raju TS, Jordan RE (2012) Galactosylation variations in marketed therapeutic antibodies. MAbs 4(3):385–391
Sareneva T et al (1995) N-glycosylation of human interferon-gamma – glycans at Asn-25 are critical for protease resistance. Biochem J 308:9–14
Wright A, Morrison SL (1997) Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol 15(1):26–32
Spearman M, Butler M (2015) Glycosylation in cell culture. Anim Cell Cult 9:237–258
Sola RJ, Griebenow K (2010) Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs 24(1):9–21
Wright A et al (1991) Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure. EMBO J 10(10):2717–2723
Angata T, Varki A (2002) Chemical diversity in the sialic acids and related alpha-keto acids: an evolutionary perspective. Chem Rev 102(2):439–469
Harduin-Lepers A et al (2001) The human sialyltransferase family. Biochimie 83(8):727–737
Wang Q et al (2015) Strategies for engineering protein N-glycosylation pathways in mammalian cells. Methods Mol Biol 1321:287–305
Chung CY et al (2015) Assessment of the coordinated role of ST3GAL3, ST3GAL4 and ST3GAL6 on the alpha 2,3 sialylation linkage of mammalian glycoproteins. Biochem Biophys Res Commun 463(3):211–215
Stencel-Baerenwald JE et al (2014) The sweet spot: defining virus–sialic acid interactions. Nat Rev Microbiol 12:739
Ashwell G, Harford J (1982) Carbohydrate-specific receptors of the liver. Annu Rev Biochem 51:531–554
Cole ES et al (1993) In vivo clearance of tissue plasminogen-activator – the complex role of sites of glycosylation and level of sialylation. Fibrinolysis 7(1):15–22
Kanda Y et al (2007) Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics. J Biotechnol 130(3):300–310
Shields RL et al (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgammaRIII and antibody-dependent cellular toxicity. J Biol Chem 277:26733–26740
Liu J et al (2015) O-glycan repertoires on a mucin-type reporter protein expressed in CHO cell pools transiently transfected with O-glycan core enzyme cDNAs. J Biotechnol 199:77–89
Chung S et al (2012) Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcgamma receptor binding and antibody-dependent cell-mediated cytotoxicity activities. MAbs 4(3):326–340
Kanda Y et al (2007) Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 17(1):104–118
Beuger V et al (2009) Short-hairpin-RNA-mediated silencing of fucosyltransferase 8 in Chinese-hamster ovary cells for the production of antibodies with enhanced antibody immune effector function. Biotechnol Appl Biochem 53(Pt 1):31–37
Imai-Nishiya H et al (2007) Double knockdown of α1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC. BMC Biotechnol 7(1):84
Yamane-Ohnuki N et al (2004) Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 87(5):614–622
Mori K et al (2004) Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol Bioeng 88(7):901–908
Malphettes L et al (2010) Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies. Biotechnol Bioeng 106(5):774–783
Sealover NR et al (2013) Engineering Chinese hamster ovary (CHO) cells for producing recombinant proteins with simple glycoforms by zinc-finger nuclease (ZFN)—mediated gene knockout of mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase (Mgat1). J Biotechnol 167(1):24–32
Sakuma T et al (2015) Homologous recombination-independent large gene cassette knock-in in CHO cells using TALEN and MMEJ-directed donor plasmids. Int J Mol Sci 16(10):23849
Ronda C et al (2014) Accelerating genome editing in CHO cells using CRISPR Cas9 and CRISPy, a web-based target finding tool. Biotechnol Bioeng 111(8):1604–1616
Grav LM et al (2015) One-step generation of triple knockout CHO cell lines using CRISPR/Cas9 and fluorescent enrichment. Biotechnol J 10(9):1446–1456
Chan KF et al (2016) Inactivation of GDP-fucose transporter gene (Slc35c1) in CHO cells by ZFNs, TALENs and CRISPR-Cas9 for production of fucose-free antibodies. Biotechnol J 11(3):399–414
Ferrara C et al (2006) Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol Bioeng 93(5):851–861
Patnaik SK, Stanley P (2006) Lectin-resistant CHO glycosylation mutants. Methods Enzymol 416:159–182
Tong C et al (2011) Generating gene knockout rats by homologous recombination in embryonic stem cells. Nat Protoc 6(6):827–844
Chan KF, Goh JSY, Song Z (2014) Improving sialylation of recombinant biologics for enhanced therapeutic efficacy. Pharm Bioprocess 2(5):363–366
Goh JS et al (2010) RCA-I-resistant CHO mutant cells have dysfunctional GnT I and expression of normal GnT I in these mutants enhances sialylation of recombinant erythropoietin. Metab Eng 12(4):360–368
Iskratsch T et al (2009) Specificity analysis of lectins and antibodies using remodeled glycoproteins. Anal Biochem 386(2):133–146
Goh JS et al (2014) Producing recombinant therapeutic glycoproteins with enhanced sialylation using CHO-gmt4 glycosylation mutant cells. Bioengineered 5(4):269–273
Goh JS et al (2014) Highly sialylated recombinant human erythropoietin production in large-scale perfusion bioreactor utilizing CHO-gmt4 (JW152) with restored GnT I function. Biotechnol J 9(1):100–109
Gaj T, Gersbach CA, Barbas CF (2013) ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31(7):397–405
Cristea S et al (2013) In vivo cleavage of transgene donors promotes nuclease-mediated targeted integration. Biotechnol Bioeng 110(3):871–880
Louie S et al (2016) FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality. Biotechnol Bioeng 114(3):632–644
Davies J et al (2001) Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng 74(4):288–294
Fukuta K et al (2000) Control of bisecting GlcNAc addition to N-linked sugar chains. J Biol Chem 275(31):23456–23461
Fukuta K et al (2000) Genetic engineering of CHO cells producing human interferon-gamma by transfection of sialyltransferases. Glycoconj J 17(12):895–904
Fukuta K et al (2000) Remodeling of sugar chain structures of human interferon-gamma. Glycobiology 10(4):421–430
Reinl T et al (2013) Golgi engineering of CHO cells by targeted integration of glycosyltransferases leads to the expression of novel Asn-linked oligosaccharide structures at secretory glycoproteins. BMC Proc 7(6):P84
Demetriou M et al (2001) Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 409(6821):733–739
Misaizu T et al (1995) Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin. Blood 86(11):4097–4104
Park SS et al (2012) Effective correction of experimental errors in quantitative proteomics using stable isotope labeling by amino acids in cell culture (SILAC). J Proteome 75(12):3720–3732
Yin B et al (2015) Glycoengineering of Chinese hamster ovary cells for enhanced erythropoietin N-glycan branching and sialylation. Biotechnol Bioeng 112(11):2343–2351
Bierhuizen MF, Fukuda M (1992) Expression cloning of cDNA encoding UDP-GlcNAc:Gal beta 1-3-GalNAc-R (GlcNAc to GalNAc) beta 1-6GlcNAc transferase by gene transfer into CHO cells expressing polyoma large tumor antigen. Proc Natl Acad Sci U S A 89(19):9326–9330
Prati EG et al (2000) Engineering of coordinated up- and down-regulation of two glycosyltransferases of the O-glycosylation pathway in Chinese hamster ovary (CHO) cells. Biotechnol Bioeng 68(3):239–244
Minch SL, Kallio PT, Bailey JE (1995) Tissue plasminogen activator coexpressed in Chinese hamster ovary cells with alpha(2,6)-sialyltransferase contains NeuAc alpha(2,6)Gal beta(1,4)Glc-N-AcR linkages. Biotechnol Prog 11(3):348–351
Krzewinski-Recchi MA et al (2003) Identification and functional expression of a second human beta-galactoside alpha2,6-sialyltransferase, ST6Gal II. Eur J Biochem 270(5):950–961
Lee EU, Roth J, Paulson JC (1989) Alteration of terminal glycosylation sequences on N-linked oligosaccharides of Chinese hamster ovary cells by expression of beta-galactoside alpha 2,6-sialyltransferase. J Biol Chem 264(23):13848–13855
Damiani R et al (2009) Stable expression of a human-like sialylated recombinant thyrotropin in a Chinese hamster ovary cell line expressing alpha2,6-sialyltransferase. Protein Expr Purif 67(1):7–14
Weikert S et al (1999) Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins. Nat Biotechnol 17(11):1116–1121
Raymond C et al (2015) Production of IgGs with a human-like sialylation in CHO cells. BMC Proc 9(Suppl 9):O3
Jeong YT et al (2008) Enhanced sialylation of recombinant erythropoietin in CHO cells by human glycosyltransferase expression. J Microbiol Biotechnol 18(12):1945–1952
Wong NS, Yap MG, Wang DI (2006) Enhancing recombinant glycoprotein sialylation through CMP-sialic acid transporter over expression in Chinese hamster ovary cells. Biotechnol Bioeng 93(5):1005–1016
Jeong YT et al (2009) Enhanced sialylation of recombinant erythropoietin in genetically engineered Chinese-hamster ovary cells. Biotechnol Appl Biochem 52(Pt 4):283–291
Son YD et al (2011) Enhanced sialylation of recombinant human erythropoietin in Chinese hamster ovary cells by combinatorial engineering of selected genes. Glycobiology 21(8):1019–1028
Burg M, Muthing J (2001) Characterization of cytosolic sialidase from Chinese hamster ovary cells: part I: cloning and expression of soluble sialidase in Escherichia coli. Carbohydr Res 330(3):335–346
Ngantung FA et al (2006) RNA interference of sialidase improves glycoprotein sialic acid content consistency. Biotechnol Bioeng 95(1):106–119
Munzert E et al (1997) Production of recombinant human antithrombin III on 20-L bioreactor scale: correlation of supernatant neuraminidase activity, desialylation, and decrease of biological activity of recombinant glycoprotein. Biotechnol Bioeng 56(4):441–448
Ferrari J et al (1998) Chinese hamster ovary cells with constitutively expressed sialidase antisense RNA produce recombinant DNase in batch culture with increased sialic acid. Biotechnol Bioeng 60(5):589–595
Van Dyk DD et al (2003) Identification of cellular changes associated with increased production of human growth hormone in a recombinant Chinese hamster ovary cell line. Proteomics 3(2):147–156
Zhang M et al (2010) Enhancing glycoprotein sialylation by targeted gene silencing in mammalian cells. Biotechnol Bioeng 105(6):1094–1105
Tousi F, Hancock WS, Hincapie M (2011) Technologies and strategies for glycoproteomics and glycomics and their application to clinical biomarker research. Anal Methods 3(1):20–32
Zhang Y, Yin H, Lu H (2012) Recent progress in quantitative glycoproteomics. Glycoconj J 29(5–6):249–258
Ito S, Hayama K, Hirabayashi J (2009) Enrichment strategies for glycopeptides. Methods Mol Biol 534:195–203
Hua S, An HJ (2012) Glycoscience aids in biomarker discovery. BMB Rep 45(6):323–330
Furukawa J-i, Fujitani N, Shinohara Y (2013) Recent advances in cellular glycomic analyses. Biomol Ther 3(1):198
Bennun SV et al (2013) Integration of the transcriptome and glycome for identification of glycan cell signatures. PLoS Comput Biol 9(1):e1002813
Ranzinger R et al (2011) GlycomeDB—a unified database for carbohydrate structures. Nucleic Acids Res 39(Database issue):D373–D376
von der Lieth CW et al (2011) EUROCarbDB: an open-access platform for glycoinformatics. Glycobiology 21(4):493–502
Akune Y et al (2010) The RINGS resource for glycome informatics analysis and data mining on the web. OMICS 14(4):475–486
Lutteke T et al (2006) GLYCOSCIENCES.de: an Internet portal to support glycomics and glycobiology research. Glycobiology 16(5):71R–81R
Krambeck FJ et al (2009) A mathematical model to derive N-glycan structures and cellular enzyme activities from mass spectrometric data. Glycobiology 19(11):1163–1175
Yang S, Zhang H (2014) Glycomic analysis of glycans released from glycoproteins using chemical immobilization and mass spectrometry. Curr Protoc Chem Biol 6(3):191–208
Tian Y, Zhang H (2010) Glycoproteomics and clinical applications. Proteomics Clin Appl 4(2):124–132
Megger DA et al (2013) Label-free quantification in clinical proteomics. Biochim Biophys Acta 1834(8):1581–1590
Kashyap MK et al (2010) SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome. Cancer Biol Ther 10(8):796–810
Tian Y, Bova GS, Zhang H (2011) Quantitative glycoproteomic analysis of optimal cutting temperature-embedded frozen tissues identifying glycoproteins associated with aggressive prostate cancer. Anal Chem 83(18):7013–7019
Raso C et al (2012) Characterization of breast cancer interstitial fluids by TmT labeling, LTQ-Orbitrap Velos mass spectrometry, and pathway analysis. J Proteome Res 11(6):3199–3210
Zhang H et al (2003) Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 21(6):660–666
Baycin-Hizal D et al (2012) Proteomic analysis of Chinese hamster ovary cells. J Proteome Res 11(11):5265–5276
Yang S et al (2015) QUANTITY: an isobaric tag for quantitative glycomics. Sci Rep 5:17585
Sun S et al (2016) Comprehensive analysis of protein glycosylation by solid-phase extraction of N-linked glycans and glycosite-containing peptides. Nat Biotechnol 34(1):84–88
Toghi Eshghi S et al (2015) GPQuest: a spectral library matching algorithm for site-specific assignment of tandem mass spectra to intact N-glycopeptides. Anal Chem 87(10):5181–5188
Furukawa J et al (2015) Quantitative O-glycomics by microwave-assisted beta-elimination in the presence of pyrazolone analogues. Anal Chem 87(15):7524–7528
Lauc G et al (2010) Genomics meets glycomics—the first GWAS study of human N-glycome identifies HNF1α as a master regulator of plasma protein fucosylation. PLoS Genet 6(12):e1001256
Huffman JE et al (2011) Polymorphisms in B3GAT1, SLC9A9 and MGAT5 are associated with variation within the human plasma N-glycome of 3533 European adults. Hum Mol Genet 20(24):5000–5011
Zoldos V et al (2012) Epigenetic silencing of HNF1A associates with changes in the composition of the human plasma N-glycome. Epigenetics 7(2):164–172
Saldova R et al (2011) 5-AZA-2′-deoxycytidine induced demethylation influences N-glycosylation of secreted glycoproteins in ovarian cancer. Epigenetics 6(11):1362–1372
Nairn AV et al (2012) Regulation of glycan structures in murine embryonic stem cells: combined transcript profiling of glycan-related genes and glycan structural analysis. J Biol Chem 287(45):37835–37856
Tan Z et al (2014) Altered N-glycan expression profile in epithelial-to-mesenchymal transition of NMuMG cells revealed by an integrated strategy using mass spectrometry and glycogene and lectin microarray analysis. J Proteome Res 13(6):2783–2795
Yang Z et al (2015) Engineered CHO cells for production of diverse, homogeneous glycoproteins. Nat Biotechnol 33(8):842–844
Chenu S et al (2003) Reduction of CMP-N-acetylneuraminic acid hydroxylase activity in engineered Chinese hamster ovary cells using an antisense-RNA strategy. Biochim Biophys Acta 1622(2):133–144
Zhang X, Lok SH, Kon OL (1998) Stable expression of human alpha-2,6-sialyltransferase in Chinese hamster ovary cells: functional consequences for human erythropoietin expression and bioactivity. Biochim Biophys Acta 1425(3):441–452
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Heffner, K.M., Wang, Q., Hizal, D.B., Can, Ö., Betenbaugh, M.J. (2018). Glycoengineering of Mammalian Expression Systems on a Cellular Level. In: Rapp, E., Reichl, U. (eds) Advances in Glycobiotechnology. Advances in Biochemical Engineering/Biotechnology, vol 175. Springer, Cham. https://doi.org/10.1007/10_2017_57
Download citation
DOI: https://doi.org/10.1007/10_2017_57
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-69589-7
Online ISBN: 978-3-030-69590-3
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)